Research
Argus Research Upgrades Integra LifeSciences to Buy From Hold, $25 Price Target
Integra LifeSciences Holdings (IART) has an average rating of hold and mean price target of $16.71, according to analysts polled by FactSet.
$IART
$IART
4 stories mentioning IARTUpdated 5d ago
Every FINWIRES story that references IART, newest first.
Research
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Adjusts Price Target to $16 From $11
Integra LifeSciences Holdings (IART) has an average rating of hold and mean price target of $16.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$IART
Wire
Truist Adjusts Price Target on Integra LifeSciences to $14 From $12, Maintains Hold Rating
Integra LifeSciences (IART) has an average rating of hold and mean price target of $17.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $13.34, Change: $+0.12, Percent Change: +0.91%
$IART
Wire
Integra LifeSciences Q1 Adjusted Earnings, Revenue Increase; Shares Rise
Integra LifeSciences Holdings (IART) shares were up past 21% in early trading on Tuesday after the company reported Q1 adjusted earnings and revenue that rose year on year and beat analysts' estimates.The company reported Q1 adjusted earnings of $0.54 per diluted share, up from $0.41 a year earlier. Analysts polled by FactSet expected $0.40.Revenue for the quarter ended March 31 was $391.9 million, up from $382.7 million a year earlier. Analysts surveyed by FactSet expected $381.8 million.For Q2, the company expects adjusted EPS of $0.44 to $0.52 and revenue of $410 million to $425 million. Analysts polled by FactSet expect $0.53 and $427.5 million.For 2026, the company now expects adjusted EPS of $2.40 to $2.50, up from $2.30 and $2.40 previously, and it reiterated the revenue outlook of $1.662 billion to $1.702 billion. Analysts surveyed by FactSet expect $2.34 and $1.67 billion, respectively.Separately, the company said Tuesday that Chairman Stuart Essig has been named president and chief executive officer. Essig will continue to serve as chair, Integra said, adding that he succeeds Mojdeh Poul, who is pursuing other opportunities.Additionally, Michael McBreen, currently executive vice president, president, Codman Specialty Surgical, has been named chief commercial officer, Integra said.Price: $13.10, Change: $+2.45, Percent Change: +23.00%
$IART
